D. D. Richman

3.8k total citations
44 papers, 3.2k citations indexed

About

D. D. Richman is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, D. D. Richman has authored 44 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Virology, 29 papers in Infectious Diseases and 13 papers in Epidemiology. Recurrent topics in D. D. Richman's work include HIV Research and Treatment (34 papers), HIV/AIDS drug development and treatment (26 papers) and HIV/AIDS Research and Interventions (18 papers). D. D. Richman is often cited by papers focused on HIV Research and Treatment (34 papers), HIV/AIDS drug development and treatment (26 papers) and HIV/AIDS Research and Interventions (18 papers). D. D. Richman collaborates with scholars based in United States, United Kingdom and Spain. D. D. Richman's co-authors include Richard S. Kornbluth, C. David Pauza, Patrick H. Cleveland, Dennis A. Carson, James R. Munis, Richard E. Chaisson, Joel E. Gallant, Jeanne Keruly, Chihiro Terai and Jacques Corbeil and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

D. D. Richman

43 papers receiving 3.1k citations

Peers

Countries citing papers authored by D. D. Richman

Since Specialization

Citations

This map shows the geographic impact of D. D. Richman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. D. Richman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. D. Richman more than expected).

Fields of papers citing papers by D. D. Richman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. D. Richman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. D. Richman. The network helps show where D. D. Richman may publish in the future.

Co-authorship network of co-authors of D. D. Richman

This figure shows the co-authorship network connecting the top 25 collaborators of D. D. Richman. A scholar is included among the top collaborators of D. D. Richman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. D. Richman. D. D. Richman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phylogenetic Analysis of Population-Based and Deep Sequencing Data to Identify Coevolving Sites in the nef Gene of HIV-1 2009 ·Molecular Biology and Evolution ·Art F. Y. Poon, Luke C. Swenson, Winnie Dong, Wanyin Deng, Sergei L. Kosakovsky Pond, Zabrina L. Brumme, James I. Mullins, D. D. Richman, P. Richard Harrigan, Simon D. W. Frost	53
2	Estimating selection pressures on HIV‐1 using phylogenetic likelihood models 2008 ·Statistics in Medicine ·Sergei L. Kosakovsky Pond, Art F. Y. Poon, Selene Zárate, Davey M. Smith, Susan J. Little, Satish K. Pillai, Ronald J. Ellis, Joseph K. Wong, Andrew Brown, D. D. Richman, Simon D. W. Frost	17
3	Clinical Utility of HIV Standard Genotyping among Antiretroviral-Naive Individuals with Unknown Duration of Infection 2007 ·Clinical Infectious Diseases ·Davey M. Smith, (unknown), Rick L. Pesano, Edward R. Cachay, (unknown), Yolanda Lie, D. D. Richman, Susan J. Little	37
4	Using mixtures of amino acids to detect individual- and population-level selection of HIV-1 protease 2005 ·Antiviral Therapy ·(unknown), (unknown), Davey M. Smith, D. D. Richman, Andrew Brown	1
5	Benefits and limitations of testing for resistance to HIV drugs 2004 ·Journal of Antimicrobial Chemotherapy ·D. D. Richman	14
6	An individual-based epidemiological model for the transmission of drug resistant HIV 2002 ·Antiviral Therapy ·Andrew Brown, (unknown), Eric S. Daar, Lionel Perrin, D. D. Richman, Susan J. Little	2
7	A Randomized Trial of the Activity and Safety of Ro 24-7429 (Tat Antagonist) versus Nucleoside for Human Immunodeficiency Virus Infection 1995 ·The Journal of Infectious Diseases ·Richard Haubrich, Charles Flexner, Michael M. Lederman, Martin Hirsch, Carla Pettinelli, Richard S. Ginsberg, Paul S. Lietman, Fayez M. Hamzeh, Stephen A. Spector, D. D. Richman	26
8	Lack of Association between Acyclovir Use and Survival in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine 1995 ·The Journal of Infectious Diseases ·Joel E. Gallant, (unknown), Jeanne Keruly, D. D. Richman, Richard E. Chaisson, (unknown)	15
9	Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine 1992 ·The Journal of Infectious Diseases ·Joel E. Gallant, (unknown), D. D. Richman, Jeanne Keruly, Richard E. Chaisson, (unknown)	440
10	Impact of Pneumocystis carinii and Cytomegalovirus on the Course and Outcome of Atypical Pneumonia in Advanced Human Immunodeficiency Virus Disease 1992 ·The Journal of Infectious Diseases ·Samuel A. Bozzette, (unknown), (unknown), Liane M. McGlynn, J. Allen McCutchan, D. D. Richman, (unknown)	55
11	Concurrent Human Immunodeficiency Virus and Mycobacterial Infection of Macrophages In Vitro Does Not Reveal any Reciprocal Effect 1992 ·The Journal of Infectious Diseases ·Pascal Meylan, James R. Munis, D. D. Richman, Richard S. Kornbluth	31
12	Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. 1991 ·Journal of Clinical Investigation ·Chihiro Terai, Richard S. Kornbluth, C. David Pauza, D. D. Richman, Dennis A. Carson	373
13	Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction 1991 ·The Journal of Infectious Diseases ·D. D. Richman, J C Guatelli, Jonathan M. Grimes, Anastasios A. Tsiatis, T Gingeras	87
14	Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodeficiency virus type 1 infection of CEM cells. 1990 ·The Journal of Experimental Medicine ·C. David Pauza, (unknown), D. D. Richman	100
15	Human immunodeficiency virus-1 infection of macrophages in vitro neither induces tumor necrosis factor (TNF)/cachectin gene expression nor alters TNF/cachectin induction by lipopolysaccharide. 1990 ·Journal of Clinical Investigation ·James R. Munis, D. D. Richman, Richard S. Kornbluth	57
16	Alternative splice acceptor utilization during human immunodeficiency virus type 1 infection of cultured cells 1990 ·Journal of Virology ·J C Guatelli, T Gingeras, D. D. Richman	91
17	Safety and Efficacy of zidovudine in asymptomatic HIV infected individuals withless than 500 CD4+ cells/mm3. 1990 ·Paul Volberding, Stephen W. Lagakos, (unknown), C B Pettinelli, (unknown), (unknown), (unknown), (unknown), (unknown), Hirsch Hirsch, Robert L. Murphy, (unknown), (unknown), (unknown), (unknown), T. C. Merigan, (unknown), D. D. Richman, (unknown), Lawrence Corey	5
18	Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. 1989 ·The Journal of Experimental Medicine ·Richard S. Kornbluth, Philip Oh, James R. Munis, Patrick H. Cleveland, D. D. Richman	250
19	Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. 1988 ·PubMed ·D. D. Richman, John C. Andrews	44
20	Rapid Viral Diagnosis 1984 ·The Journal of Infectious Diseases ·D. D. Richman, Patrick H. Cleveland, (unknown), Michael N. Oxman, Geoffrey M. Wahl	105

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact